Data from ASCO 2026 show talazoparib improved rPFS
EYNOTE-905 shows QoL stability
CROWN shows long-term lorlatinib benefit
Optimizing biomarker use in second‑line care
Real‑world complexity in long‑term management
Expert consensus statement on LOPD care
We also report on a new use for artificial intelligence that could help eliminate some racial inequities in heart disease diagnoses.
We also report on two more studies involving wildly popular GLP-1 weight-loss drugs, including one that shows promise in treating alcohol abuse.
We also report on a study that reveals why females are more prone to autoimmune diseases.
We also report on a study that found an alarming trend in medical research papers.
We also report on findings that help explain why the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.
We also report on a potential new use for another approved medicine that helped reduce suicidal thoughts in patients with severe depression when added to the psychedelic drug ketamine.
We also report on a large analysis that found little clinical anti-fracture benefit from vitamin D or calcium supplements, and a study that suggests insurers may be cutting off sleep apnea patients from their CPAP machines prematurely.
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice-changing.
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
